International Society for Influenza and other Resp
Post# of 148184
Wednesday, October 7
15.35-15.50 GMT
(10.35-10.50 AM EST)
A Phase 2 Study of Leronlimab for Mild to Moderate Coronavirus
Disease 2019 (COVID-19)
- Harish Seethamraju, Montefiore Medical Center, Bronx, NY, USA
https://isirv.org/site/images/conferences/AVG...tember.pdf